BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 10195258)

  • 1. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
    Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy.
    García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R
    Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment.
    Comanor L; Anderson F; Ghany M; Perrillo R; Heathcote EJ; Sherlock C; Zitron I; Hendricks D; Gordon SC
    Am J Gastroenterol; 2001 Oct; 96(10):2968-72. PubMed ID: 11693334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays.
    Sarrazin C; Teuber G; Kokka R; Rabenau H; Zeuzem S
    Hepatology; 2000 Oct; 32(4 Pt 1):818-23. PubMed ID: 11003628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome detection in liver and peripheral blood mononuclear cells: predictor factors of sustained response in patients with chronic hepatitis C.
    Berenguer M; Olaso V; Córdoba J; Gobernado M; Carrasco D; Berenguer J
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):899-903. PubMed ID: 8574725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
    Kinai E; Hanabusa H; Kato S
    J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C.
    Xu DZ; Xie Y; Li ZQ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):550-3. PubMed ID: 16286260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
    Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
    J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.